Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer | Zendy

Mayada Aljehani | Zendy; John W. Morgan | Zendy; Laurel A. Guthrie | Zendy; Brice Jabo | Zendy; Majed Ramadan | Zendy; Khaled Bahjri | Zendy; Sharon S. Lum | Zendy; Matthew J. Selleck | Zendy; Mark E. Reeves | Zendy; Carlos A. Garberoglio | Zendy; Maheswari Senthil | Zendy

Open Access

Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer

Author(s) -

Mayada Aljehani,

John W. Morgan,

Laurel A. Guthrie,

Brice Jabo,

Majed Ramadan,

Khaled Bahjri,

Sharon S. Lum,

Matthew J. Selleck,

Mark E. Reeves,

Carlos A. Garberoglio,

Maheswari Senthil

Publication year - 2017

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2017.3466

Subject(s) - medicine , cetuximab , bevacizumab , colorectal cancer , kras , oncology , hazard ratio , population , cancer , chemotherapy , confidence interval , environmental health

Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that right- or left-sided primary tumor origin affects survival and response to BT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research